Modality
Bispecific Ab
MOA
GLP-1/GIP
Target
DLL3
Pathway
Amyloid
MS
Development Pipeline
Preclinical
~Jul 2017
→ ~Oct 2018
Phase 1
~Jan 2019
→ ~Apr 2020
Phase 2
~Jul 2020
→ ~Oct 2021
Phase 3
Jan 2022
→ Jan 2028
Phase 3Current
NCT06258536
90 pts·MS
2022-03→2026-03·Terminated
NCT05195042
1,535 pts·MS
2022-01→2028-01·Recruiting
NCT04026435
1,129 pts·MS
2023-07→TBD·Terminated
+1 more trial
4,631 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-03-024w agoPh3 Readout· MS
2028-01-071.8y awayPh3 Readout· MS
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P3
Recruit…
P3
Termina…
P3
Recruit…
P3
Termina…
Catalysts
Ph3 Readout
2026-03-02 · 4w ago
MS
Ph3 Readout
2028-01-07 · 1.8y away
MS
RecruitingTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06258536 | Phase 3 | MS | Terminated | 90 | ACR20 |
| NCT05195042 | Phase 3 | MS | Recruiting | 1535 | CfB |
| NCT04026435 | Phase 3 | MS | Terminated | 1129 | UPCR |
| NCT03364656 | Phase 3 | MS | Recruiting | 1877 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7809 | Pfizer | Phase 1 | DLL3 | |
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zenonesiran | GSK | Preclinical | DLL3 | |
| AMG-7379 | Amgen | Preclinical | DLL3 | |
| ARG-1924 | Argenx | Preclinical | DLL3 | |
| Cevinaritide | Genmab | Phase 2/3 | DLL3 |